The Australian Centre for HIV and Hepatitis Virology Research (ACH2) is seeking expressions of interest (EoI) in applied research from qualified scientists to fund research projects aimed at:
- developing vaccine candidates for HIV, HBV subtypes, HCV or HTLV-1;
- developing preventatives such as HIV microbicides and pre-exposure prophylaxis (PrEP);
- cure and treatment interventions for HIV, HBV, or HTLV-1;
- novel diagnostics and prognostics for HIV, HBV, HCV, HTLV-1 or hepatitis B/C/HIV/HTLV-1 co-infection;
- molecular tools for tracking epidemics caused by these viruses; and
- development of new tests for supporting vaccine and antiviral trials.
Grants based on the specimens obtained from the Immunovirology Research Network collected from clinical trials or cohort studies of patients with HIV, HBV or HCV are also encouraged.
These grants are intended to complement and translate basic research into the virology and immunology of HIV, HBV, HCV and HTLV-1, usually initially funded by other granting bodies.
Funding & Duration
Funding is available from 1 January 2019 to 30 September 2019 for grants up to AUD $100,000.
- Chief investigators (CIs) must be equivalent to NHMRC PSP 4, usually with independent funding.
- Basic research is not eligible, and grants aimed at development of new direct-acting antivirals against HCV are also not eligible.
Submission Requirements & Due Date
- Applications must be submitted for internal review by 29 October 2018
- Please complete your RFR through ResearchMaster. When prompted to Select Fund Scheme use Fund Scheme code ORG105111
- See also: Submitting an Application to Research Services for Review